Enriqueta Felip
Vall d'Hebron Hospital Universitari
3 papers in the Anchorcite directory, published between 2015 and 2018, cited 22,521 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Lung Cancer Treatments and Mutations · 3 papers
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Research Studies · 1 paper
Frequent co-authors
- Leora Horn · 2 papers
- Naiyer A. Rizvi · 2 papers
- Leena Gandhi · 2 papers
- Rina Hui · 2 papers
- Edward B. Garon · 2 papers
- Hossein Borghaei · 1 paper
- Luis G Paz-Ares · 1 paper
- David Robert Spigel · 1 paper
Papers
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
Metadata from OpenAlex (CC0).